Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fingolimod.
about
Remyelination therapy for multiple sclerosisLysophospholipids and their receptors in the central nervous systemFingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapyFingolimod for the treatment of neurological diseases-state of play and future perspectivesThe Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple SclerosisOverview and safety of fingolimod hydrochloride use in patients with multiple sclerosis.Myelin recovery in multiple sclerosis: the challenge of remyelinationMechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices.ASP4058, a novel agonist for sphingosine 1-phosphate receptors 1 and 5, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profileFingolimod for relapsing multiple sclerosis: an update.Neurobiological effects of sphingosine 1-phosphate receptor modulation in the cuprizone model.Heterogeneity of oligodendrocyte progenitor cells in adult human brainCeramide synthesis is modulated by the sphingosine analog FTY720 via a mixture of uncompetitive and noncompetitive inhibition in an Acyl-CoA chain length-dependent manner.Fingolimod modulates microglial activation to augment markers of remyelination.Fingolimod prevents blood-brain barrier disruption induced by the sera from patients with multiple sclerosis.Induction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastomaDiffusion tensor imaging detects treatment effects of FTY720 in experimental autoimmune encephalomyelitis mice.Fingolimod and related compounds in a spontaneous autoimmune polyneuropathy.Roles for lysophospholipid S1P receptors in multiple sclerosis.Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions.FTY720 on the way from the base camp to the summit of the mountain: relevance for remyelination.Signaling and regulatory functions of bioactive sphingolipids as therapeutic targets in multiple sclerosis.Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosisFrom demyelination to remyelination: the road toward therapies for spinal cord injury.Effect of Fingolimod on Neural Stem Cells: A Novel Mechanism and Broadened Application for Neural Repair.Role of Oligodendrocyte Dysfunction in Demyelination, Remyelination and Neurodegeneration in Multiple Sclerosis.The impact of fingolimod (FTY720) in neuroimmunologic diseases: mechanisms beyond immunomodulationSphingosine-1-phosphate receptor antagonism enhances proliferation and migration of engrafted neural progenitor cells in a model of viral-induced demyelination.The sphingosine 1-phosphate receptor agonist FTY720 is neuroprotective after cuprizone-induced CNS demyelination.S1P1 deletion in oligodendroglial lineage cells: Effect on differentiation and myelination.[Oral fingolimod in multiple sclerosis: therapeutic modulation of the sphingosine-1-phosphate system].Immunohistochemical detection of sphingosine-1-phosphate receptor 1 and 5 in human multiple sclerosis lesions.
P2860
Q26824246-842E1310-6B45-45F6-8CDF-6E9F843C13EBQ26859168-DA63D62B-ED3D-4B0E-9A7E-3FAB7192DD8EQ27011473-79CA9184-804F-4A2F-9CA1-8592A8D5B27FQ27026175-4E91DFD0-5503-474E-AEC8-1C6F23C58C92Q28073377-EC8D9F86-D029-4896-8E01-F1AFD75BDD6EQ30458371-6B63690B-7EBF-46F8-803A-42CD29D234C4Q33772195-FE551E99-1074-4963-96AE-E33CC58686D4Q33881977-8A0C6A2F-ABC2-4569-86B1-57176CD6E144Q33882403-B05914C0-5041-4E8F-9F0F-8D8655E46FD3Q34408450-5819EE3F-992B-4CDD-8EA4-D976FC0EB604Q34618474-1CA98D6B-61A7-47F6-9BCD-55442AF567C1Q34813347-72A9B729-62CA-407A-97A0-C8FA51B2D724Q34936700-CE812324-EBC0-4697-BB83-7075D1E8D42CQ34974825-C2F6C5E5-C912-43DA-89A5-1908D8231683Q35154946-E1BDC4D7-F679-43BC-B4E4-B82A22030774Q35578146-2AA246FC-6A8B-42BE-99DF-8A675BB32BD2Q35845241-794B984B-7851-4F4E-9908-512FED21E4A5Q37337129-04E4CFAC-C675-456F-87F5-F953DBDE055EQ37350365-9B851311-6BCE-4EF9-A7AC-B6835A9B7308Q37803419-A33FCC0A-4375-46BF-9963-6749524FD98FQ37905665-F1826EF5-68B9-4B31-962F-71BA70905C02Q37989903-A787EC77-21E4-40AD-A54C-C92F185D198AQ37997376-021745F5-E1AE-460F-B512-496D7AD5F6D1Q38216015-BC30A7A2-B8AD-42E8-BE16-93BA4F2E8A96Q38366783-900F774A-0328-40D7-A0A0-27477AF14775Q38983628-880BA936-30E7-46B0-8E71-25632E75579AQ39091396-1F724562-4163-4295-9FA2-3B381FB23A3FQ40791515-41FDA1E7-D21A-4FC2-A6D3-01C8E600CEE8Q40966857-3BC9199F-6EDC-4149-9D26-49FCF13E0280Q41958515-223D56D0-C74F-4AC3-B4C0-0237BD710F6AQ42486184-9ACC4142-7CBD-473D-8B18-7D212C586CCFQ43838770-BAD66B85-5035-4E35-AE3A-7036CA7D4D30Q44602716-3AE16255-EB78-4BBC-85C5-ACA8E237F611
P2860
Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fingolimod.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Cyclical and dose-dependent re ...... ligodendrocytes to fingolimod.
@en
type
label
Cyclical and dose-dependent re ...... ligodendrocytes to fingolimod.
@en
prefLabel
Cyclical and dose-dependent re ...... ligodendrocytes to fingolimod.
@en
P2093
P2860
P1476
Cyclical and dose-dependent re ...... oligodendrocytes to fingolimod
@en
P2093
Betty Soliven
Jeffery A Hall
Timothy E Kennedy
P2860
P304
P356
10.2353/AJPATH.2008.080478
P407
P577
2008-09-04T00:00:00Z